Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).

Read full text Summarise with VIRAT
Authors: Aycan Yüksel, Dilek Karadoğan, Nur Hürsoy, Tahsin Gökhan Telatar, Neslihan Kose, Feride Marım, İlknur Kaya, Aslıhan Banu Er, Merve Erçelik, Demet Polat Yuluğ, Merve Yumrukuz Şenel, Ceren İlgar
+9 more Ökkeş Gültekin, Selin Çakmakcı Karakaya, Bilge YILMAZ KARA, Neslihan Özçelik, İnci Selimoğlu, Kübra Uyar Er, Abdurrahman Kotan, Hasan Veysel Keskin, Metin Akgün
Cited by: 0
References: 29

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND AND AIM: Post-COVID-19 Interstitial Lung Disease (ILD) is controversial and need for treatment is unclear.The aim of this study was to investigate the efficacy of methylprednisolone in the management of post-COVID-19 ILD in comparison to standard of care. METHODS: In this multicentre, randomized controlled clinical trial, patients with post-COVID ILD were assigned to two groups: the steroid group received oral methylprednisolone at a dose of 0.5 mg/kg/day, while the control group received supportive therapy. The primary outcome was proportion of patients with functional improvement (defined as the absence of hypoxemia/desaturation during 6MWT) at twelve-weeks. RESULTS: A total of 229 patients with post-COVID ILD patients (124 in the steroid group and 104 in the control group) completed the study. At 12-weeks, functional improvement rate was higher in the steroid group compared to the control group (74.2% vs. 55.2%, OR:2.33 [95% CI:1.34-4.06], p=0.0041). Radiological improvement was observed in 61.3% of the steroid group compared to 46.7% of the controls (OR:1.81 [95% CI:1.07-3.06], p=0.037). The mean increase in FVC (7.2% vs 3.7%, p=0.03), 6MW distance (91 vs 41 meters, p

Fields of Study & Subjects

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Long-Term Effects of COVID-19 COVID-19 Clinical Research Studies

Publication details

Journal / source
Sarcoidosis vasculitis and diffuse lung diseases
Volume
43
Issue
1
Pages
17022–17022
Publication date
27 March 2026
Language
EN